脑富集环状RNA血液生物标志物可预测SSRI抗抑郁药反应
该研究基于EMBARC和ANTARES两个独立临床队列的基线全血样本,采用环状RNA特异性PCR检测发现,治疗前CDR1as在SSRI舍曲林未来应答者与非应答者间差异表达。自然主义抗抑郁反应研究进一步提示CDR1as与SSRI类抗抑郁药效应相关,且CDR1as水平可特异性预测SSRI治疗的缓解,而不能预测安慰剂或安非他酮的反应/缓解。动物机制和神经元培养研究提示小鼠Cdr1as受5-HT2A和BDNF受体信号调控。
要点
- 治疗前全血CDR1as表达可区分舍曲林未来应答者与非应答者。
- CDR1as可特异性预测SSRI治疗的缓解,但不预测安慰剂或安非他酮。
- 小鼠Cdr1as受5-HT2A和BDNF受体信号调控,支持其机制关联。
核心结论
- 脑富集环状RNA CDR1as可作为血液生物标志物,用于预测SSRI治疗的反应和缓解。
研究设计与样本
- 研究使用环状RNA特异性PCR检测两个独立临床队列EMBARC和ANTARES的基线全血样本,并纳入自然主义抗抑郁反应研究、动物机制和神经元培养研究。
主要发现
- 治疗前CDR1as在舍曲林未来症状应答者与非应答者之间差异表达。
- 自然主义抗抑郁反应研究显示CDR1as与SSRI类抗抑郁药效应相关。
- 应答者接受舍曲林治疗后CDR1as水平改变,且治疗后变化轨迹与长期缓解相关。
- 血液CDR1as水平可特异性预测SSRI治疗的缓解,但不能预测安慰剂或安非他酮的反应/缓解。
- 小鼠Cdr1as受5-HT2A和BDNF受体信号强烈调控。
临床怎么用
- 临床可考虑将基线全血CDR1as检测作为辅助手段,预测SSRI治疗的反应与缓解。
- CDR1as预测作用具有SSRI特异性,不适用于安慰剂或安非他酮。
- 治疗前后CDR1as水平变化轨迹可能有助于评估长期缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major Depressive Disorder (MDD) is a debilitating psychiatric disorder that is a leading cause of disability worldwide. Although treatment with antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), has demonstrated clinical efficacy, the "trial and error" approach in choosing the most effective antidepressant treatment for each patient allows for only a subset of patients to achieve response to the first line of treatment. Circular RNAs (circRNAs), are highly stable and brain-enriched non-coding RNAs that are mainly derived from the backsplicing and covalent joining of exons and introns of protein-coding genes. They are known to be important for brain development and function, cross the blood-brain-barrier, and be highly sensitive to changes in both synaptic activity and neuronal receptor signaling. Here we present evidence that expression of the brain-enriched circRNA, CDR1as, is associated with symptomatic response to SSRI treatment, and regulated by serotonin and Brain-Derived Neurotrophic Factor (BDNF) receptor activity. We present data using circRNA-specific PCR in baseline whole blood samples from two independent cohorts, drawn from the Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC) and the Biomarkers of ANTidepressant RESponse (ANTARES) clinical studies, showing that before treatment CDR1as is differentially expressed between future symptomatic responders and non-responders to treatment with the SSRI sertraline. Additional data from naturalistic antidepressant response studies further highlight the association between CDR1as and antidepressant effects of SSRIs as a class. In addition, we show that CDR1as levels are altered following sertraline treatment in responders with the trajectory of change post-treatment associated with long-term remission. Furthermore, we report that levels of CDR1as in the blood can specifically predict remission with SSRI treatment, but not response/remission with Placebo or Bupropion treatments. Lastly, we provide evidence in animal mechanistic and neuronal culture studies, suggesting mouse Cdr1as is strongly regulated by 5-HT2A and BDNF receptor signaling. Taken together, our data identify a brain-enriched circRNA associated with known mechanisms of antidepressant response that can serve as a blood biomarker for predicting response and remission with SSRI treatment.
引用
- Papageorgiou G, Ibrahim EC, Gorgievski V, et al. A brain-enriched circRNA blood biomarker can predict response to SSRI antidepressants. Mol Psychiatry. 2026. PMID: 41703266. doi:10.1038/s41380-026-03491-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。